BR112018076190A2 - ortólogos e sistemas crispr tipo vi - Google Patents

ortólogos e sistemas crispr tipo vi

Info

Publication number
BR112018076190A2
BR112018076190A2 BR112018076190A BR112018076190A BR112018076190A2 BR 112018076190 A2 BR112018076190 A2 BR 112018076190A2 BR 112018076190 A BR112018076190 A BR 112018076190A BR 112018076190 A BR112018076190 A BR 112018076190A BR 112018076190 A2 BR112018076190 A2 BR 112018076190A2
Authority
BR
Brazil
Prior art keywords
systems
orthologs
targeting
crispr type
rna
Prior art date
Application number
BR112018076190A
Other languages
English (en)
Inventor
S Lander Eric
Zhang Feng
Gootenberg Jonathan
O Abudayyeh Omar
Original Assignee
Massachusetts Inst Technology
Harvard College
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Harvard College, Broad Inst Inc filed Critical Massachusetts Inst Technology
Publication of BR112018076190A2 publication Critical patent/BR112018076190A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

a invenção fornece sistemas, métodos e composições para ácidos nucleicos de alvejamento. em particular, a invenção fornece sistemas de alvejamento de rna de ocorrência não natural ou geneticamente modificados que compreendem uma proteína efetora de crispr de alvejamento de rna inovadora e pelo menos um componente de ácido nucleico de alvejamento semelhante a um rna-guia.
BR112018076190A 2016-06-17 2017-06-19 ortólogos e sistemas crispr tipo vi BR112018076190A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662351662P 2016-06-17 2016-06-17
US201662351803P 2016-06-17 2016-06-17
US201662376377P 2016-08-17 2016-08-17
US201662410366P 2016-10-19 2016-10-19
US201662432240P 2016-12-09 2016-12-09
US201762471792P 2017-03-15 2017-03-15
US201762484786P 2017-04-12 2017-04-12
PCT/US2017/038154 WO2017219027A1 (en) 2016-06-17 2017-06-19 Type vi crispr orthologs and systems

Publications (1)

Publication Number Publication Date
BR112018076190A2 true BR112018076190A2 (pt) 2019-06-18

Family

ID=59295312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076190A BR112018076190A2 (pt) 2016-06-17 2017-06-19 ortólogos e sistemas crispr tipo vi

Country Status (9)

Country Link
US (3) US11788083B2 (pt)
EP (1) EP3455357A1 (pt)
JP (3) JP7267013B2 (pt)
KR (2) KR20190019168A (pt)
CN (1) CN109642231A (pt)
AU (4) AU2017283713B2 (pt)
BR (1) BR112018076190A2 (pt)
CA (1) CA3028158A1 (pt)
WO (1) WO2017219027A1 (pt)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11435358B2 (en) 2011-06-23 2022-09-06 Board Of Regents, The University Of Texas System Single molecule peptide sequencing
WO2016069124A1 (en) 2014-09-15 2016-05-06 Board Of Regents, The University Of Texas System Improved single molecule peptide sequencing
DE112012002570B4 (de) 2011-06-23 2023-11-23 Board Of Regents, The University Of Texas System Identifizieren von Peptiden auf der Einzelmolekülebene
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3215617B1 (en) 2014-11-07 2024-05-08 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
EP3294896A1 (en) 2015-05-11 2018-03-21 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
CN116334142A (zh) 2015-06-09 2023-06-27 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
EP3786294A1 (en) 2015-09-24 2021-03-03 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
WO2017091630A1 (en) 2015-11-23 2017-06-01 The Regents Of The University Of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP3443086B1 (en) 2016-04-13 2021-11-24 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3523426A4 (en) 2016-09-30 2020-01-22 The Regents of The University of California RNA GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHOD FOR USE THEREOF
EA201990860A1 (ru) 2016-09-30 2019-10-31 Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
PT3551753T (pt) 2016-12-09 2022-09-02 Harvard College Diagnósticos baseados num sistema efetor de crispr
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11739308B2 (en) * 2017-03-15 2023-08-29 The Broad Institute, Inc. Cas13b orthologues CRISPR enzymes and systems
US11021740B2 (en) 2017-03-15 2021-06-01 The Broad Institute, Inc. Devices for CRISPR effector system based diagnostics
US11104937B2 (en) 2017-03-15 2021-08-31 The Broad Institute, Inc. CRISPR effector system based diagnostics
US11174515B2 (en) * 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
KR102687373B1 (ko) 2017-03-23 2024-07-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3610009A1 (en) 2017-04-12 2020-02-19 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
US11618928B2 (en) 2017-04-12 2023-04-04 The Broad Institute, Inc. CRISPR effector system based diagnostics for malaria detection
CA3059956A1 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
EP3615672A1 (en) 2017-04-28 2020-03-04 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
JP7398279B2 (ja) 2017-05-10 2023-12-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｃｒｉｓｐｒ／ｃａｓ９核送達による細胞ｒｎａの狙いを定めた編集
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
EP3635104A1 (en) 2017-06-09 2020-04-15 Editas Medicine, Inc. Engineered cas9 nucleases
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US20200248169A1 (en) * 2017-06-26 2020-08-06 The Broad Institute, Inc. Crispr/cas-cytidine deaminase based compositions, systems, and methods for targeted nucleic acid editing
US11168322B2 (en) 2017-06-30 2021-11-09 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
JP2020537516A (ja) * 2017-10-04 2020-12-24 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化された核酸編集のためのシステム、方法、及び組成物
RU2020115264A (ru) 2017-10-04 2021-11-08 Зе Броад Институт, Инк. Диагностика на основе эффекторной системы crispr
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US20200332272A1 (en) * 2017-10-23 2020-10-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2019089808A1 (en) 2017-11-01 2019-05-09 The Regents Of The University Of California Class 2 crispr/cas compositions and methods of use
AU2018358051A1 (en) 2017-11-01 2020-05-14 The Regents Of The University Of California CasZ compositions and methods of use
US11332736B2 (en) 2017-12-07 2022-05-17 The Broad Institute, Inc. Methods and compositions for multiplexing single cell and single nuclei sequencing
EP3728576A4 (en) * 2017-12-22 2021-11-24 The Broad Institute, Inc. CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF RNA BASES
KR20200111180A (ko) * 2017-12-22 2020-09-28 더 브로드 인스티튜트, 인코퍼레이티드 Crispr 이펙터 시스템 기반 다중 진단
JP7527961B2 (ja) * 2018-01-29 2024-08-05 ザ・ブロード・インスティテュート・インコーポレイテッド Ｃｒｉｓｐｒエフェクター系に基づく診断
CN108559738A (zh) * 2018-02-12 2018-09-21 南昌大学 一种植物rna修饰和编辑的系统及方法
EP4257696A3 (en) 2018-03-14 2024-01-24 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
FI3765616T3 (fi) 2018-03-14 2023-08-29 Arbor Biotechnologies Inc Uusia CRISPR-DNA- ja RNA-kohdennusentsyymejä ja -järjestelmiä
WO2019189827A1 (ja) * 2018-03-30 2019-10-03 国立大学法人 岡山大学 核酸構築物、医薬組成物、抗がん剤、抗ウイルス剤及び抗菌剤
CN108796036B (zh) * 2018-04-03 2021-11-19 交弘生物科技(上海)有限公司 基于原核Argonaute蛋白的核酸检测方法及其应用
US11795456B2 (en) 2018-04-16 2023-10-24 Georgia Tech Research Corporation MRNA driven expression of RNA editors for treatment of pathologies
CN112513250A (zh) * 2018-04-20 2021-03-16 加利福尼亚大学董事会 用于跟踪和操纵细胞rna的融合蛋白和融合核糖核酸
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
CN108546718B (zh) * 2018-05-16 2021-07-09 康春生 crRNA介导的CRISPR/Cas13a基因编辑系统在肿瘤细胞中的应用
US20210198664A1 (en) 2018-05-16 2021-07-01 Arbor Biotechnologies, Inc. Novel crispr-associated systems and components
CN110527697B (zh) * 2018-05-23 2023-07-07 中国科学院分子植物科学卓越创新中心 基于CRISPR-Cas13a的RNA定点编辑技术
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement
CA3102211A1 (en) 2018-06-26 2020-01-02 The Broad Institute, Inc. Crispr double nickase based amplification compositions, systems, and methods
US20210269866A1 (en) 2018-06-26 2021-09-02 The Broad Institute, Inc. Crispr effector system based amplification methods, systems, and diagnostics
WO2020000454A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 一种表达LwCas13a基因的质粒、构建方法及其应用
CN112469832A (zh) * 2018-07-23 2021-03-09 德克萨斯大学系统董事会 蛋白质上的翻译后修饰的单分子测序鉴别
WO2020022461A1 (ja) * 2018-07-25 2020-01-30 国立研究開発法人産業技術総合研究所 植物における標的ｄｎａのメチル化を抑制する方法
SG11202102068TA (en) * 2018-07-31 2021-03-30 Broad Inst Inc Novel crispr enzymes and systems
EP3830301B1 (en) 2018-08-01 2024-05-22 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
EP3847255A4 (en) * 2018-09-06 2024-01-10 The Regents of The University of California ADAR RECRUITMENT DEVELOPED RNA AND DNA BASE EDITING
EP3650553B1 (en) * 2018-11-07 2023-07-12 Siemens Healthcare GmbH Method for detection of specific nucleic acids
MX2021005702A (es) 2018-11-14 2021-09-21 Massachusetts Inst Technology Multiplexión de variantes virales altamente evolutivas con sherlock.
MX2021005701A (es) 2018-11-14 2021-09-23 Broad Inst Inc Sistema crispr a base de sistemas y métodos de diagnóstico de gotas.
EP3882345A4 (en) * 2018-11-15 2023-02-22 China Agricultural University CRISPR-CAS12J ENZYME AND SYSTEM
WO2020102659A1 (en) * 2018-11-15 2020-05-22 The Broad Institute, Inc. G-to-t base editors and uses thereof
WO2020124050A1 (en) 2018-12-13 2020-06-18 The Broad Institute, Inc. Tiled assays using crispr-cas based detection
EP3931313A2 (en) 2019-01-04 2022-01-05 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020186231A2 (en) 2019-03-14 2020-09-17 The Broad Institute, Inc. Crispr effector system based multiplex diagnostics
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
JP2022526908A (ja) 2019-03-19 2022-05-27 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
AU2020248911B2 (en) * 2019-03-26 2022-12-15 Edigene Inc. Method for identifying functional elements
CN109913502A (zh) * 2019-04-16 2019-06-21 和元生物技术（上海）股份有限公司 一种Cas9-gRNA表达系统及其应用
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
US20220403356A1 (en) * 2019-07-12 2022-12-22 Duke University 3' utr crispr-dcas 13 engineering system and methods of using same
CN110819652A (zh) * 2019-08-21 2020-02-21 山东金城生物药业有限公司 一种谷氨酸棒杆菌同时基因敲除及基因表达抑制的双功能系统及应用
WO2021046257A1 (en) 2019-09-03 2021-03-11 The Broad Institute, Inc. Crispr effector system based multiplex cancer diagnostics
JP2022546592A (ja) 2019-09-03 2022-11-04 マイエロイド・セラピューティクス，インコーポレーテッド ゲノム組込みのための方法および組成物
CA3151563A1 (en) * 2019-09-20 2021-03-25 Feng Zhang Novel type vi crispr enzymes and systems
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
EP4069842A1 (en) 2019-12-02 2022-10-12 Shape Therapeutics Inc. Therapeutic editing
EP4100424A2 (en) * 2020-02-07 2022-12-14 University of Rochester Targeted translation of rna with crispr-cas13 to enhance protein synthesis
CN111337666B (zh) * 2020-02-12 2021-04-02 山东大学 I-motif重组介导的FRET探针及其原位成像癌细胞表面蛋白质同源二聚化的应用
WO2021168799A1 (en) * 2020-02-28 2021-09-02 Huigene Therapeutics Co., Ltd. Type vi-e and type vi-f crispr-cas system and uses thereof
US11851702B2 (en) 2020-03-23 2023-12-26 The Broad Institute, Inc. Rapid diagnostics
AU2021267940A1 (en) 2020-05-08 2022-12-08 President And Fellows Of Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
JP7419168B2 (ja) * 2020-06-10 2024-01-22 株式会社東芝 改変型ｐｉｇｇｙＢａｃトランスポゼースのポリペプチド、それをコードするポリヌクレオチド、導入キャリア、キット、細胞のゲノムに目的配列を組込む方法及び細胞製造方法
EP4222253A1 (en) * 2020-09-30 2023-08-09 HuidaGene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
WO2022068912A1 (en) 2020-09-30 2022-04-07 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
WO2022188039A1 (en) 2021-03-09 2022-09-15 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
CN112430586B (zh) * 2020-11-16 2021-09-07 珠海舒桐医疗科技有限公司 一种VI-B型CRISPR/Cas13基因编辑系统及其应用
CN116917478A (zh) * 2020-12-22 2023-10-20 亥姆霍兹慕尼黑中心-德国健康与环境研究中心(有限公司) Crispr/cas13在rna病毒和/或细菌诱导的疾病的治疗中的应用
WO2022149568A1 (ja) * 2021-01-05 2022-07-14 学校法人 川崎学園 ヒトを含めた生物の細胞にある転写産物および、遺伝子導入されたｒｎａとその複合体精製ツール
US20240102007A1 (en) 2021-06-01 2024-03-28 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
WO2023282710A1 (ko) * 2021-07-08 2023-01-12 한국과학기술원 Cas13 단백질의 활성 조절을 통한 rna 발현 조절 또는 편집 방법
WO2023004391A2 (en) 2021-07-21 2023-01-26 Montana State University Nucleic acid detection using type iii crispr complex
EP4215612A1 (en) * 2022-01-20 2023-07-26 Sartorius Stedim Cellca GmbH Genome editing with crispr/cas nucleases comprising collateral activity
WO2024173645A1 (en) 2023-02-15 2024-08-22 Arbor Biotechnologies, Inc. Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
GB9114259D0 (en) 1991-07-02 1991-08-21 Ici Plc Plant derived enzyme and dna sequences
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
BR9306802A (pt) 1992-07-27 1998-12-08 Pioneer Hi Bred Int Processo independente de genótipos para produção de planta de soja transgénica e processo de regeneração de plantas de soja a partir de nodos cotiledonais
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1994026877A1 (en) 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5789156A (en) 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
AU698739B2 (en) 1995-06-06 1998-11-05 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
JP4303418B2 (ja) 1997-10-24 2009-07-29 ライフ テクノロジーズ コーポレーション 組換え部位を有する核酸を使用する組換えクローニング
US6750059B1 (en) 1998-07-16 2004-06-15 Whatman, Inc. Archiving of vectors
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7868149B2 (en) 1999-07-20 2011-01-11 Monsanto Technology Llc Plant genome sequence and uses thereof
US6603061B1 (en) 1999-07-29 2003-08-05 Monsanto Company Agrobacterium-mediated plant transformation method
GB0024550D0 (pt) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7776321B2 (en) 2001-09-26 2010-08-17 Mayo Foundation For Medical Education And Research Mutable vaccines
GB0125216D0 (en) 2001-10-19 2001-12-12 Univ Strathclyde Dendrimers for use in targeted delivery
US20090100536A1 (en) 2001-12-04 2009-04-16 Monsanto Company Transgenic plants with enhanced agronomic traits
JP2005512598A (ja) 2001-12-21 2005-05-12 オックスフォード バイオメディカ （ユーケー） リミテッド Ｅｉａｖなどのレンチウイルス発現ベクターを使用するトランスジェニック生物の作製方法
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
EP1558724A4 (en) 2002-11-01 2006-08-02 New England Biolabs Inc ORGANIC RNA SCREENING AND ITS USE IN INTERRUPTING GENE TRANSMISSION IN THE ENVIRONMENT
NZ544637A (en) 2003-07-16 2010-04-30 Protiva Biotherapeutics Inc Lipid encapsulated interfering RNA
NZ581166A (en) 2003-09-15 2011-06-30 Protiva Biotherapeutics Inc Polyethyleneglycol-modified lipid compounds and uses thereof
GB0325379D0 (en) 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
EP2397490B1 (en) 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
GB0422877D0 (en) 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
WO2007048046A2 (en) 2005-10-20 2007-04-26 Protiva Biotherapeutics, Inc. Sirna silencing of filovirus gene expression
WO2007049731A1 (ja) 2005-10-28 2007-05-03 Mitsubishi Tanabe Pharma Corporation 新規細胞膜透過ペプチド
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
JP2008078613A (ja) 2006-08-24 2008-04-03 Rohm Co Ltd 窒化物半導体の製造方法及び窒化物半導体素子
WO2008042156A1 (en) 2006-09-28 2008-04-10 Northwestern University Maximizing oligonucleotide loading on gold nanoparticle
CA2670096A1 (en) 2006-11-21 2008-05-29 The Samuel Roberts Noble Foundation, Inc. Biofuel production methods and compositions
WO2008149176A1 (en) 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
CA2711179A1 (en) 2007-12-31 2009-07-16 Nanocor Therapeutics, Inc. Rna interference for the treatment of heart failure
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
JP2011523557A (ja) 2008-06-04 2011-08-18 メディカル リサーチ カウンシル ペプチド
JP2011526619A (ja) 2008-06-30 2011-10-13 サイレンシード リミテッド 局所ドラッグデリバリーシステム、その方法、および、その組成物
EP2309980A1 (en) 2008-07-08 2011-04-20 S.I.F.I. Societa' Industria Farmaceutica Italiana Ophthalmic compositions for treating pathologies of the posterior segment of the eye
AU2009311667B2 (en) 2008-11-07 2016-04-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
GB2465749B (en) 2008-11-25 2013-05-08 Algentech Sas Plant cell transformation method
US20120047601A1 (en) 2009-02-17 2012-02-23 The Regents Of The University Of California Method of Reducing Acetylation in Plants to Improve Biofuel Production
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US8236943B2 (en) 2009-07-01 2012-08-07 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein B
US20110027239A1 (en) 2009-07-29 2011-02-03 Tissue Genesis, Inc. Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer
US8927807B2 (en) 2009-09-03 2015-01-06 The Regents Of The University Of California Nitrate-responsive promoter
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
US20120003201A1 (en) 2010-04-21 2012-01-05 Nicholas Susanne B Vault agents for chronic kidney disease
JP5952263B2 (ja) 2010-04-26 2016-07-13 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガーヌクレアーゼを使ったｒｏｓａ遺伝子座のゲノム編集
US8372951B2 (en) 2010-05-14 2013-02-12 National Tsing Hua University Cell penetrating peptides for intracellular delivery
EP2575894B1 (en) 2010-05-28 2015-02-25 Oxford Biomedica (UK) Ltd Delivery of lentiviral vectors to the brain
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA-AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20120295960A1 (en) 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
WO2013033436A1 (en) 2011-09-01 2013-03-07 University Of Iowa Research Foundation Oligonucleotide-based probes for detection of bacterial nucleases
PT2791160T (pt) 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
US20130185823A1 (en) 2012-01-16 2013-07-18 Academia Sinica Mesoporous silica nanoparticle-mediated delivery of dna into arabidopsis root
LT3241902T (lt) * 2012-05-25 2018-06-25 The Regents Of The University Of California Būdai ir kompozicijos, skirti rnr nukreiptos tikslinės dnr modifikacijai ir rnr nukreiptos transkripcijos moduliacijai
US8614194B1 (en) 2012-07-25 2013-12-24 Kaohsiung Medical University Anionic cell penetrating peptide and its use for intracellular delivery
CN116622704A (zh) 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
CN110592089B (zh) 2012-10-23 2022-11-01 基因工具股份有限公司 用于切割靶dna的组合物及其用途
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
DK2771468T3 (en) 2012-12-12 2015-05-26 Broad Inst Inc Production systems, processes and optimized drive configurations for sequence manipulation
KR20150105956A (ko) 2012-12-12 2015-09-18 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
PL2931898T3 (pl) 2012-12-12 2016-09-30 Le Cong Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
PL2784162T3 (pl) 2012-12-12 2016-01-29 Broad Inst Inc Opracowanie systemów, metod oraz zoptymalizowanych kompozycji przewodnikowych do manipulacji sekwencyjnej
WO2014093595A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
DK2898075T3 (en) 2012-12-12 2016-06-27 Broad Inst Inc CONSTRUCTION AND OPTIMIZATION OF IMPROVED SYSTEMS, PROCEDURES AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
JP6702858B2 (ja) 2013-06-17 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド ウイルス成分を使用して障害および疾患をターゲティングするためのＣＲＩＳＰＲ−Ｃａｓ系および組成物の送達、使用および治療上の適用
EP3011035B1 (en) 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
AU2014281026B2 (en) 2013-06-17 2020-05-28 Massachusetts Institute Of Technology Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
DK3011031T3 (da) 2013-06-17 2020-12-21 Broad Inst Inc Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi
EP3011032B1 (en) 2013-06-17 2019-10-16 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
KR20160034901A (ko) 2013-06-17 2016-03-30 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작에 최적화된 ｃｒｉｓｐｒ-ｃａｓ 이중 닉카아제 시스템, 방법 및 조성물
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
US9068179B1 (en) * 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
EP3079726B1 (en) 2013-12-12 2018-12-05 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA3012631A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
CN109153980B (zh) * 2015-10-22 2023-04-14 布罗德研究所有限公司 Vi-b型crispr酶和系统
EP3390624A4 (en) * 2015-12-18 2019-07-10 The Regents of The University of California MODIFIED POLYPEPTIDES AND METHOD OF USE THEREOF
MX2018008416A (es) * 2016-01-08 2019-11-11 Univ California Polipéptidos heterodímericos condicionalmente activos y métodos para su uso.
US11427837B2 (en) * 2016-01-12 2022-08-30 The Regents Of The University Of California Compositions and methods for enhanced genome editing
WO2017136335A1 (en) * 2016-02-01 2017-08-10 The Regents Of The University Of California Self-inactivating endonuclease-encoding nucleic acids and methods of using the same
JP6998313B2 (ja) * 2016-02-11 2022-02-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞のゲノムにおける変異ジストロフィン遺伝子を修飾する方法及び組成物
WO2017160752A1 (en) * 2016-03-14 2017-09-21 Intellia Therapeutics, Inc. Methods and compositions for gene editing
TWI773666B (zh) * 2016-03-30 2022-08-11 美商英特利亞醫療公司 Crispr/cas 組分之脂質奈米粒子調配物
US20190093128A1 (en) * 2016-03-31 2019-03-28 The Regents Of The University Of California Methods for genome editing in zygotes
WO2017189336A1 (en) * 2016-04-25 2017-11-02 The Regents Of The University Of California Methods and compositions for genomic editing
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
PT3551753T (pt) * 2016-12-09 2022-09-02 Harvard College Diagnósticos baseados num sistema efetor de crispr
US11021740B2 (en) * 2017-03-15 2021-06-01 The Broad Institute, Inc. Devices for CRISPR effector system based diagnostics
US11174515B2 (en) * 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics

Also Published As

Publication number Publication date
EP3455357A1 (en) 2019-03-20
KR20190019168A (ko) 2019-02-26
AU2023204078A1 (en) 2023-07-13
JP2023052051A (ja) 2023-04-11
AU2021203747B2 (en) 2023-11-09
AU2018271372A1 (en) 2019-01-17
CA3028158A1 (en) 2017-12-21
JP2019524072A (ja) 2019-09-05
AU2017283713B2 (en) 2021-04-08
US20230383282A1 (en) 2023-11-30
KR20230156150A (ko) 2023-11-13
WO2017219027A1 (en) 2017-12-21
US11788083B2 (en) 2023-10-17
JP2023134453A (ja) 2023-09-27
AU2017283713A1 (en) 2018-12-20
US20190359971A1 (en) 2019-11-28
US20240191223A1 (en) 2024-06-13
CN109642231A (zh) 2019-04-16
AU2021203747A1 (en) 2021-07-01
JP7267013B2 (ja) 2023-05-01

Similar Documents

Publication Publication Date Title
BR112018076190A2 (pt) ortólogos e sistemas crispr tipo vi
AU2018251801A8 (en) Novel type VI CRISPR orthologs and systems
MX2020011939A (es) Nuevas enzimas y sistemas crispr.
EP4361261A3 (en) Novel cas13b orthologues crispr enzymes and systems
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
AU2018320870A1 (en) RNA targeting methods and compositions
EP3645054A4 (en) COMPOSITIONS BASED ON CRISPR / CAS-ADENIN-DEAMINASE, SYSTEMS AND METHODS FOR TARGETED NUCLEIC ACID EDITING
WO2017127807A8 (en) Crystal structure of crispr cpf1
EP3692145A4 (en) NUCLEIC ACID TARGETED EDITING SYSTEMS, METHODS AND COMPOSITIONS
EP3684397A4 (en) SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED EDITION OF NUCLEIC ACIDS
EP3701025A4 (en) SYSTEMS, PROCEDURES AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
MX2020006072A (es) Métodos y composiciones relacionados con cpf1 para la edición genica.
EP3701042A4 (en) SYSTEMS, PROCEDURES AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
WO2016154127A3 (en) Compositions and methods for treating hypertriglyceridemia
EA201991555A1 (ru) Композиции и способы усиления или увеличения продукции ifn i типа
BR112018010805A2 (pt) mutantes de proteína f de rsv
WO2018109170A3 (en) Il-11ra antibodies
MX2018001497A (es) Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
WO2015191693A3 (en) Method for gene editing
WO2015023975A8 (en) Compositions and methods for modulating rna
SG10201803042PA (en) Anti-tim-3 antibodies
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
WO2018094356A3 (en) Compositions and methods for target nucleic acid modification
IL266131A (en) Compositions for reprogramming cells into dendritic cells or antigen-presenting cells, methods and uses thereof

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements